ProCE Banner Activity

SWOG S0777: VRd Vs Rd in Previously Untreated MM

Slideset Download
Conference Coverage
Addition of bortezomib to lenalidomide plus dexamethasone induction significantly improves survival in patients with newly diagnosed MM without plans for immediate ASCT.

Released: December 07, 2015

Expiration: December 05, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Millennium Takeda

Seagen